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We are pleased to be given the opportunity to read and respond to the peer commen-
taries onour ‘regulatory soup’ essay1 byBarthaKnoppers2 andShawnHarmon.3 Knop-
pers framesher response as a dichotomybetween regulation and collaboration, and em-
phasizes the role of patient/participant/public engagement as the key to ensuring that
precisionmedicine and its associated infrastructure operates appropriately. In contrast,
Harmon focuses on regulatory tools that may be employed to ensure that ‘innovations
are timely, widely affordable, safe, and effective’. In particular, he draws attention to the
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ways in which ‘responsible research and innovation’4 and ‘legal foresighting’5 can be
used as tools for developing ‘values-based regulation’.6
Both peer commentaries focus particularly on biobanking anddata sharing.Herewe
reflect on developments in this field since ‘regulatory soup’ was written.We pay partic-
ular attention to our work with colleagues at the Centre for Law and Genetics at the
University of Tasmania, Australia and our collaborative endeavors with like-minded
scholars in other jurisdictions, some of whom also co-authored the regulatory soup es-
say. Coincidentally our work incorporates many of the ideas expressed in both peer
commentaries, with a particular focus on collaborative engagement, identification of
values, reflexivity and evidence-based review. We end with a practical example of how
we have used these values-based approaches to create a governance framework for a
new type of bioresource in Tasmania.
It could well be argued that biobanking and data sharing raise no new regulatory
concerns requiring new responses. UK Biobank and its equivalents have been around
for a decade and more, and their establishment was premised on having robust ethical
and governance frameworks in place from the outset. One of the triggers for our recent
research is the questions that are being raised about the ongoing viability of these types
of biobanks and whether the governance arrangements that have been developed im-
pose impossible obligations. Underutilization of stored tissue samples has been a sur-
prise to many, as has the demise of some seemingly well-established and well-funded
biobanks.7 On reflection, however, this could have been predicted. We have learned
much from the early biobanks and models for biobank governance. Here, we list three
key issues relating to tissue and data collection and governance, drawn from our own
experience, anecdotal conversations and reports in the academic literature.
i. Tissue collection. Many of the early biobanks aimed to collect a multitude of
different types of tissues including fresh frozen tissue, serum, plasma, whole
blood, and other more specific tissue types. Additionally, some of the tissues
required specialized processing, including the development of tissue microar-
rays.Themore diverse the types of tissues collected andmore complex process-
ing required, the larger the laboratory team required to fulfil operational needs.
This led to a call for biobanking collection procedures to be embedded within
pathology departments to better streamline consent andpermit processing pro-
cedures to preserve the integrity of tissues. However, this raised challenges for
pathology staff in balancing the demands of providing clinical and research ser-
vices and conducting these additional activities when already operating on lim-
ited budgetry resources.8
4 RichardOwen, PhilMacnaghten& Jack Stilgoe,Responsible Research and Innovation: From Science in Society to
Science for Society, With Society, 39 SCI. & PUB. POL’Y. 751 (2012).
5 Graeme Laurie, ShawnH. E. Harmon& Fabiana Arzuaga, Foresighting Futures: Law, New Technologies and the
Challenges of Regulating for Uncertainty, 4 L. INNOVATION &TECH. 1 (2012). See also the various references in
Harmon, supra note 3, at 682.
6 See particularly Harmon, supra note 3, at 684–686.
7 Neil Stephens & Rebecca Dimond, Closure of a Human Tissue Biobank: Individual, Institutional, and Field Ex-
pectations during Cycles of Promise and Disappointment, 34 NEWGENET. & SOC. 417 (2015).
8 For examples, see Monya Baker, Building Better Biobanks, 486 NATURE 141 (2012).
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ii. Data collection. Many biobanks also collected general health data from partici-
pants.These datasets initially proved useful for early studies, butwere limited to
the health information provided at the time. Some, but not all anticipated longi-
tudinal follow-up.However, participantswho subsequently becameunavailable
for follow-up, for reasons including death, disinterestedness, loss of contact or
whatever else, limited the value of these datasets for longitudinal applications.
Longitudinal data collection is also expensive and an ongoing burden on the
finances of biobanks.
iii. Governance. Complex governance, consent and operating frameworks insti-
gated to inspire community confidence and encourage community participa-
tion could turn out to be expensive to maintain, difficult to fulfil in terms of
promised obligations to participants, and challenging in terms of adherence
to community concerns over private investment in face of an expectation that
biobanks should become self-sustainable.9
All of the above resulted in difficulties in reaching recruitment targets, inability to
demonstrate broad utility of the samples collected, and lack of widespread uptake.
Early cost recovery models were prohibitively expensive and restrictive material trans-
fer agreements (MTAs) reduced the ability of researchers to readily access materials
on terms that gave them freedom to do the research and engage with the collaborators
of their choice.10 There was concern that biobanks were ‘staggeringly expensive’ to op-
erate, and this, together with the need to secure ongoing funding commitments, was
always likely to threaten their survival in the long run.11
In ‘Has the Biobank Bubble Burst’, describes three waves of biobanking that have
resonance with Knoppers‘ 3 Rs: establishment of biobank governance and manage-
ment frameworks; moves toward collaboration and standardization; and recognition
of a need to develop new business methods to ensure sustainability.The paper goes on
to identify various recurring themes that need to be tackled for future sustainability. In
summary, these include consent requirements; ongoing connection with participants;
properly maintaining tissue storage; responding to rapidly changing technology; and
funding sustainability.Despite the challenges, biobanks continue to offer rich resources
for biomedical research, provided that the genomic and other data they generate can be
made broadly available.
Several technological and administrative advances in recent times have addressed
some of these issues:
9 We discuss community concerns relating to commercial involvement in biobanking in Dianne Nicol et al.,
Understanding Public Reactions to Commercialization of Biobanks and Use of Biobank Resources, SOC. SCI. &
MED. (2016) doi: 10.1016/j.socscimed.2016.06.028.
10 MarcoCapocasa et al.,Samples andDataAccessibility inResearchBiobanks: anExplorative Survey, PEERJ. (2016)
doi: 10.7717/peerj.1613.
11 See Don Chalmers et al.,Has the Biobank Bubble Burst? Withstanding the Challenges for Sustainable Biobanking
in the Digital Era, BMC MED. ETHICS (2016) doi: 10.1186/s12910-016-0124-2, including attribution of the
phrase ‘staggeringly expensive’ to Hank Greely.
4  Implementing values-based governance for a new bioresource model
i. Advances in available technologies for tissue collection and storage.The imper-
ative of balancing participant needswithminimizing costs andmaximizing con-
venience and utility has driven technological advances. For example, method-
ologies have been developed that permit routinely collected and archived fixed
paraffin-embedded tissues to be used for broader purposes, including the use of
next-generation sequencing technologies.
ii. More selective tissue collection.The recognition that tissue samples are expen-
sive to collect and process and the absence of an integrated collection program
in pathology departments has led to a re-evaluation ofwhat should be collected.
Depending on the circumstances, it may be more appropriate to choose the
types of samples to be collected on a project by project basis rather than em-
ploying a blanket rule that all tissue samples should be collected at all times,
irrespective of likely utility or cost.
iii. Improved data linkage. Government investment in health data linkage has
largely overcome the need to collect and store comprehensive health informa-
tion for each of their samples. This means that biobank samples can be linked
to relevant health data to answer questions that are tailored to the nature of the
data available. This approach reduces the requirement to anticipate all possi-
ble future needs, and eliminates duplicate collection and storage of data already
held by government or private institutional bodies.
iv. Re-evaluation of cost recovery andMTA terms. Recognition that practiceswith
regard to cost recovery and MTAs were becoming barriers to the wide use of
samples in research has led to greater recognition of the value of open sharing
and use of simple standard formMTAs.
New approaches to governance are required in order to address these issues, par-
ticularly to minimize bureaucracy. At the same time, it is essential to pay due regard to
the complex ethical, legal, and social implications and public concerns associated with
tissue and data sharing. Legal requirements, institutional and human research ethics
obligations, and the need to secure and maintain public trust could all constrain free
and open sharing of genomic data and related activities. A range of considerationsmust
be taken into account in tackling this complex issue. Given that genomic data is shared
across borders, responsesmust also consider international dimensions and, where pos-
sible, strive for global harmonization without weak links in the regulatory chain. More-
over, regulatory responses must achieve community acceptance and legitimacy; oper-
ational effectiveness; and responsiveness to the inevitable changes in data sharing and
in the science itself.12 Rights, responsibilities, and stewardship need to be reviewed in
this fluid, changing, and global environment.13 A balance must be achieved, fostering
widespread sharing and innovation on the one hand, but ensuring adequate ethical and
12 Roger Brownsword, Regulating Human Genetics: New Dilemmas for a New Millennium, 12 MED. L. REV. 14
(2004).
13 Roger Brownsword, Rights, responsibility and stewardship: beyond consent, in THE GOVERNANCE OF GENETIC
INFORMATION: WHODECIDES? (Heather Widdows & CarolineMullen eds., 2009) ch. 5.
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legal protections for individual research participants and patients, their families and
communities on the other.
One clear example of an area crying out for a new approach is the process for ethical
review of research, which is still based on the one project, one place, and one point in
time model.14 Projects involving sharing of genomic data globally can be delayed by
years due to the need for each research team at each institution to obtain ethical clear-
ance. Aworking group of theGlobal Alliance forGenomicHealth has been considering
these issues for the past two years15 and recently released a draft policy to address ethics
review equivalency.16
The need for new strategies for public participation is highlighted in the Knoppers
paper. Much of her argument is based on longitudinal cohort studies. We put forward
a new participatorymodel in our ‘Has the Biobank Bubble Burst’ paper.The gist of this
model, which we refer to as the ‘walking biobank’, is that:
. . . the researchparticipants themselves serve as the storageunits of their genomicmaterial
and the researcher, rather than expending limited funds on the infrastructure tomaintain
specimens in suspended animation, invites participants in a contact database (through
dynamic consent models of contact) to ‘walk in’ to donate tissue or information as re-
quired to address a specific research question.17
Despite the value of this type of biobank model, it is unlikely to become the norm.
Clinicians will continue tomaintain biopsy collections, and project-specific collections
will remain common. Nevertheless, Knoppers’ point regarding cohort studies having
alwaysmaintained contact with participants to varying degrees is a good one, and high-
lights potential mechanisms for the types of flexibility, adaptability, and responsiveness
we called for in original paper.
In an area of biomedical research like genomics, where it is essential for large num-
bers of willing participants to engage, particularly for the longitudinal cohort studies
mentioned by Knoppers, public trust is vital.18 To maintain public trust, changes to
biobank management and regulatory reform must incorporate appropriate public en-
gagement.19 We acknowledge the importance of public engagement, and include it as
an essential component of our own work, but it is far from the whole story. While the
focus onpublic collaboration and engagement suggestedbyKnoppersmaymeet the re-
quirements of ethical research, and sits well at the base of John Braithwaite’s regulatory
pyramid,20 it ignores the important role of regulation at the upper part of the pyramid
in providing incentives for stakeholders to act in ethical ways (or disincentives to act in
unethical ways), and providing redress when things go wrong.
14 Edward S Dove et al., Ethics Review for International Data-intensive Research, 351 SCIENCE 1399 (2016).
15 David Townend et al., Streamlining Ethical Review of Data Intensive Research, 354 BMJ 4181 (2016).
16 https://genomicsandhealth.org/work-products-demonstration-projects/ethics-review-recognition-policy
(accessed February 23, 2016).
17 Chalmers et al., supra note 11, at 10.
18 Christine Critchley & Dianne Nicol, Commercialisation of Genomic Research: the Issue of Public Trust in TEN-
SIONS AND TRAUMAS IN HEALTH LAW (Ian Freckleton & Kerry Petersen, 2017).
19 NUFFIELD COUNCIL ON BIOETHICS, PUBLIC PARTICIPATION SHOULD BE AT THE HEART OF BIG DATA PROJECTS.
REPORT (2015).
20 John Braithwaite,The Essence of Responsive Regulation, 44 UBC L. REV. 475 (2011).
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While essential, there are limits to the utility of public engagement and collabora-
tion: individuals often can’t understand the full extent of what they’re consenting to.
This works as an imperfect control on biobanking and data sharing as individuals may
not object to actions harmful to them, or may object to safe actions, undermining pub-
lic benefit. Moreover, many segments of the population experience ‘research fatigue’
or the burden of research, curtailing their willingness and capability to participate to
the extent outlined by Knoppers. On the other hand, having these options available
for those who wish to engage does enhance public trust, as does the transparency and
accountability engendered by such an approach.
In answer to Knoppers’ titular question, then, we answer not one or the other, but
rather appropriate collaboration is essential to effective, responsive, and flexible reg-
ulation. This perspective is supported by Harmon’s arguments. He extends the utility
of this balanced approach through drawing a sensible parallel between the regulatory
requirements of precision medicine infrastructure and those necessitated by emerging
technologies and innovative medical therapies. Harmon’s view of value-based regula-
tion refers to values in two senses:
i. Values about society—well-being, dignity, justice, and autonomy.
ii. Values about science and its governance—integrity, transparency, engagement,
and reflexivity.21
He concludes, however, that the majority of existing and emerging biobanks fail to
adopt a prospective values-based governance strategy.22 We agree that this demands
new and sustained practices for thinking about governance.
An example of how these considerations might be put into practice is provided by
ReD TIGER (the Repository of Donations of Tasmanians in Genetic and Epidemio-
logical Research), in which we have been involved as part of the team developing the
governance framework.This is a new form of biorepository that takes into account the
experiences and limitations of older style biobanks and builds a governance framework
based on the types of values identified by Harmon.
In seeking to establish aTasmanian biorepository, the founders weremotivated by a
desire to reduce the burden on participants, tomake better use of existing resources, to
facilitate high-quality research, and to reflect community values. To this end, commu-
nity engagement was undertaken prospectively and formed the foundation of the gov-
ernance framework. Survey results and the findings of a deliberative democracy were
analysed to identify the key issues that would influence public trust in a Tasmanian
biorepository.23 These included a focus on research that would benefit Tasmanians;
community involvement as a formal component of governance; acceptability of com-
mercialization provided it does not hinder research and commercial interests do not
control the biorepository.
The sustainability of the biorepository was a significant theme of the discussions
within the deliberative democracy events. There was wide acknowledgement that a
21 Harmon, supra note 3, at 685.
22 Id. at 686.
23 Nicol et al., supra note 9; RebekahMcWhirter et al.,Community Engagement for Big Epidemiology: Deliberative
Democracy as a Tool, 4 J. PERS. MED. 459 (2014).
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Figure 1. Summary of the ReD TIGER biorepository model.
biorepository that was not economically viable, or that was forced to set unrealistically
high cost-recovery charges,wouldnot achieve the aimsof facilitating research, reducing
participant burdenor benefiting the community.This issue,whichhas plaguedprevious
incarnations of biobanks, was resolved through a radical reconceptualization of what
the biorepository should attempt to achieve. Instead of prospective collection, process-
ing and storage of a set range of biospecimens and accompanying data, the proposed
ReD TIGER model takes a more efficient and pared down approach, summarized in
Figure 1.
The Red TIGER model includes provisions for samples from completed research
studies which may be deposited by complying with the consent and ethical review
requirements outlined in the governance framework. New studies may utilize the
processes, documents, and multimedia consent app developed by ReD TIGER for
collection of samples to be deposited at study completion. No data, beyond the min-
imum necessary for identification, verification of consent, and data linkage, are held
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by the repository; all data linkage is undertaken in conjunction with the Tasmanian
Data Linkage Unit, providing safe, ethical, and timely access to a broad range of data
sources. Data remain with the data custodians, who may be government departments,
hospitals, or research studies, among others.Thismodelmakes efficient use of research
resources, minimizes the burden on participants, and maximizes the potential benefits
for the community, while facilitating public trust through meaningful community en-
gagement.
Large-scale biobanking and data sharing are evolving at a rapid pace, and many of
the challenges identified by ethical and legal commentators or by early experiences are
beginning to be resolved. New challenges will inevitably arise with the emergence of
new technologies and developments in social norms, but values-based governance—
as demonstrated by the ReDTIGERmodel—may well prove to be a practical, flexible,
and responsive approach for addressing nascent challenges. Public collaboration and
engagement are essential components of values-based governance. Just as importantly,
regulatory instruments need to be regularly evaluated to ensure their legitimacy, re-
sponsiveness, and effectiveness. Whilst creation of new technology-specific laws will
rarely be an appropriate response to new technological challenges, changes will be
needed if existing laws cannot be applied in ways that reflect societal and scientific
values.
